SAB_Logo.png
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
21 mai 2024 07h15 HE | SAB Biotherapeutics, Inc.
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
Centogene_Logo.png
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
13 déc. 2023 06h30 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
SAB_Logo.png
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
02 oct. 2023 07h30 HE | SAB Biotherapeutics, Inc.
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
Centogene_Logo.png
In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)
21 févr. 2023 06h30 HE | Centogene NV
FTD is a rare and rapidly progressing neurodegenerative disease caused by multiple hereditary factors, including mutations in the progranulin (GRN) geneThe observational EFRONT study is increasing the...
Centogene_Logo.png
CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics
09 janv. 2023 08h30 HE | Centogene NV
The Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of disease progression, diagnosis, and treatment for...
Centogene_Logo.png
CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics
03 oct. 2022 08h00 HE | Centogene NV
Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics...
SAB_Logo.png
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
25 févr. 2022 06h00 HE | SAB Biotherapeutics, Inc.
ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB) (Nasdaq: SABS), a...
SAB_Logo.png
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
24 janv. 2022 06h00 HE | SAB Biotherapeutics, Inc.
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700...
SAB_Logo.png
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
01 déc. 2021 07h00 HE | SAB Biotherapeutics, Inc.
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by...
Centogene_Logo.png
CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study
28 oct. 2021 06h30 HE | Centogene NV
FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN)Study will enroll and genetically...